And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
A summary of four recent studies evaluating locoregional therapies for hepatocellular carcinoma and percutaneous ablation for ...
Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC / cancer, cancer care, Cancer research, cancer ...
As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
Toyota has 20 years of data to pull from, giving it an edge over upstart Chinese firms that excel in hardware but lag Western ...
Key Insights From ESMO 2026 / A. Benmaziane, B. Chibaudel, B. Goldenberg, biopsy, Breast Cancer, C. Coutzac, C. Cremolini, C.
The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...
PCMag Middle East on MSN
Fitbit Edge Review: Google's Best Fitness Tracker With a Screen
None ...
HPE patched multiple Aruba Networking flaws that could allow attackers to take full control of affected AOS-8 and AOS-10 devices ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results